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Abstract
Background: Inappropriate use of broad-spectrum antimicrobials affects adversely both the individual patient
and the general public. The aim of the study was to identify patients at risk for excessively prolonged carbapenem
treatment in the ICU as a target for antimicrobial stewardship interventions.
Methods: Case–control study in a network of 11 ICUs of a university hospital. Patients with uninterrupted
meropenem therapy (MT) > 4 weeks were compared to controls. Controls were defined as patients who stayed
on the ICU > 4 weeks and received meropenem for ≤ 2 weeks. Associations between case–control status and
potential risk factors were determined in a multivariate logistic regression model.
Results: Between 1st of January 2013 and 31st of December 2015, we identified 36 patients with uninterrupted
MT > 4 weeks. Patients with prolonged MT were more likely to be surgical patients (72.2% of cases vs. 31.5% of
controls; p≤ 0.001) with peritonitis being the most common infection (n = 16, 44.4%). In the multivariate logistic
regression model colonization with multidrug-resistant (MDR) Gram-negative bacteria (OR 7.52; 95% CI 1.88–30.14,
p = 0.004) and the type of infection (peritonitis vs. pneumonia: OR 16.96, 95% CI 2.95–97.49) were associated with
prolonged MT.
Conclusion: Surgical patients with peritonitis and patients with known colonization with MDR Gram-negative
bacteria are at risk for excessively prolonged carbapenem therapy and represent an important target population
for antimicrobial stewardship interventions.
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Background
Antibiotics are among the most frequently prescribed
drugs in intensive care settings [1]. Administration of
antibiotics in patients has been shown to be an import-
ant risk factor for the emergence of colonization and
infection with antibiotic-resistant bacteria [1–4]. Fur-
thermore, prolonged use of antimicrobials is associated
with Clostridium difficile infection, antibiotic-related
adverse events, and increased health care costs [2].
Prolonged use of broad-spectrum antibiotics such as car-
bapenems is particularly worrying as it promotes the
spread of multidrug-resistant, difficult-to-treat pathogens.
In the present study, we analysed retrospectively pa-
tients treated with meropenem in a large centre for in-
tensive care medicine in a German university hospital.
We sought to describe the characteristics of patients
having received excessively prolonged meropenem treat-
ment, defined as uninterrupted therapy > 4 weeks, their
microbiological data, and outcome on the ICU. We
chose the duration of > 4 weeks as it indicates an in-
appropriately long use of a broad-spectrum antimicro-
bial not supported by any guideline or local standard
procedure. Our aims were i) to understand risk factors
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for excessively prolonged treatment with a carbapenem
and ii) to identify target populations for pre-emptive
antimicrobial stewardship interventions.
Methods
The University Medical Center Hamburg-Eppendorf is a
tertiary level medical centre with approx. 1600 hospital
beds and 80,000 admissions per year. The Department of
Intensive Care includes 11 ICUs with a capacity of 132
beds. Approximately 8,000 patients are admitted to the
ICUs each year, with an average length of stay on the ICU
of 4.5 days. All decisions to initiate or to discontinue anti-
microbial treatment are taken by the ICU consultants.
Meropenem was the only hospital-listed standard
carbapenem during the study period (1st of January 2013
until 31st of December 2015). In selected cases, imipe-
nem/cilastin was used on special request. These cases
were excluded from further analysis, as they did not
represent the standard prescription policy and made up
less than 7% of all carbapenem prescriptions. Doripenem
and ertapenem were not used during the study period.
Patient identification from database
Basic data on all ICU patients who received meropenem
during the study period were retrieved from the electronic
medical records (ICM, Dräger, Lübeck, Germany). Pa-
tients were grouped according to the length of ICU stay
(≤1 day, > 1 to 3 days, > 3 to 7 days, > 7 to 14 days, > 14
to 28 days, and > 28 days). The following information was
additionally retrieved for patients who remained in the
ICU for longer than 4 weeks: age (grouped as <50, 50–70
and >70 for regression analysis), sex, main diagnosis de-
fined as the main reason for ICU admission (grouped as
medical, surgical, neurosurgical-neurological), presence of
malignancy, Simplified Acute Physiology Score (SAPS
score, grouped as below median (<40) and above median
(≥40) for regression analysis), antibiotic treatment, surgical
procedures including re-operation to obtain source con-
trol, results of source control management and outcome
in the ICU.
Case–control design
Cases were defined as patients who stayed on the ICU
longer than 4 weeks and received meropenem for longer
than 4 weeks without interruption. If a patient was on
meropenem therapy while being transferred to the ICU,
the duration of meropenem therapy before admission was
added to the duration of therapy during the ICU stay.
Controls were defined as patients who stayed on the
ICU longer than 4 weeks and were treated with merope-
nem for 2 weeks or less. Meropenem therapy (MT) for ≤
2 weeks was used as a marker for guideline-adherent
prescription for ventilator-associated pneumonia, urinary
tract infection and peritonitis [5–8]. To attain optimal
statistical power, 108 controls were randomly selected
from 322 patients fulfilling the definition (3:1 ratio of con-
trols to cases) by use of a random number generator.
Data on antimicrobial resistance
All available microbiological data generated during the
hospital stay were collected for patients included in the
study. In addition, all patients were screened on admis-
sion to the ICU for colonization with the following
bacteria: nasal swab for methicillin-resistant S. aureus
(MRSA), wound swabs for MRSA, pharyngeal and deep
anal (anorectal) swabs for vancomycin-resistant enterococci
(VRE) and multidrug-resistant (MDR) Gram-negative bac-
teria. MDR Gram-negative bacteria (MRGN) were defined
as 3MRGN or 4MRGN in accordance to the current defin-
ition by the German national public health institute (Robert
Koch Institute). In brief, Enterobacteriaceae are defined as
3MRGN when resistant to ureidopenicillin/beta-lactamase
inhibitor combinations (e.g. piperacillin/tazobactam), third
generation cephalosporins (e.g. ceftriaxone) and fluoroqui-
nolones (e.g. ciprofloxacin), but susceptible to carbapenems
(e.g. meropenem). 4MRGN Enterobacteriaceae are defined
as being resistant to ureidopenicillins/beta-lactamase inhibi-
tor combinations, third generation cephalosporins, fluoro-
quinolones and carbapenems.
Statistical analysis
Summary statistics for the study participants were
expressed as proportions for dichotomous or categorical
variables with a corresponding Chi2 test and as medians
with interquartile range (IQR) for continuous variables
with a corresponding Wilcoxon rank-sum test.
Possible associations between case–control status and po-
tential risk factors were determined by calculating odds ra-
tios (OR) and 95% confidence intervals (CI). In a first step,
analysis was performed as univariate logistic regression with
the case–control status as independent variable and poten-
tial risk factors as dependent variables (i.e. age, sex, main
reason for ICU admission, presence of malignancy, SAPS
score, colonization with carbapenem-susceptible, MDR
bacteria, type of infection). All variables showing at least
some evidence of an association with case–control status
(defined as p < 0.1) were then included in a multivariate lo-
gistic regression model to adjust for potential confounding.
All data analyses were performed with Stata 12 (StataCorp
LP, College Station, USA).
Results
Selection of cases and controls
In total, 3,909 patients admitted to the ICUs during the
study period were treated with meropenem. The propor-
tion of meropenem prescriptions increased with increas-
ing length of stay (LOS), ranging from 6.4% in patients
staying between 24 and 72 h to 86.1% (606/704 patients)
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in patients with an ICU LOS of longer than 4 weeks
(Fig. 1). 322 patients with ICU LOS > 4 weeks received
uninterrupted MT ≤ 2 weeks, and 108 of these patients
were randomly selected as controls (Fig. 2). 36 patients
received uninterrupted MT for longer than 4 weeks.
One patient received meropenem twice during admis-
sion and the longer episode was counted.
Characteristics of cases and controls
The characteristics of cases and controls are summarized
in Table 1. There were no differences in age, sex, and
simplified acute physiologic score (SAPS) at admission.
Cases were more likely to be surgical patients (72.2% of
cases vs. 31.5% of controls; p ≤ 0.001), while controls
were more likely to be patients with medical conditions
(11.1% of cases vs. 42.7% of controls; p = 0.001). None of
the surgical patients with peritonitis was considered to
have the source of the abdominal infection adequately
controlled. This fact is reflected by the very high number
of re-operations in this group. Cases suffered more often
then controls from a malignant disease (47.2% of cases
vs. 20.4% of controls; p = 0.002). All malignancies in the
prolonged MT were solid tumours (n = 17), whereas in
controls 4 patients had a haematological malignancy and
18 patients a solid tumour.
Cases were colonized with 3MRGN bacteria more
often than controls (p = 0.007) and had a higher mortal-
ity on ICU (p = 0.03).
Risk factors for prolonged MT
Univariate logistic regression showed an association be-
tween prolonged MT and the presence of malignancy (OR
3.5; 95% CI 1.57-7.82, p = 0.002), colonization with
multidrug-resistant carbapenem-susceptible Gram-negative
bacteria (OR 4.12; 95% CI 1.38-12.35, p = 0.01), being a sur-
gical patient as compared to being a medical patient (OR
8.36, 95% CI 2.67-26.17, p < 0.001) and the type of infection
(p < 0.001) with a strongly increased risk for patients with
peritonitis compared to patients with pneumonia (OR
21.60, 95% CI 5.05-92.35). No association was seen for age
(p = 0.44), sex (p = 0.76) and SAPS score (p = 0.33) at
admission. In the multivariate logistic regression model
colonization with carbapenem-susceptible, multidrug-
resistant Enterobacteriaceae (OR 7.52; 95% CI 1.88-30.14,
Fig. 1 Usage of meropenem in relation to the length of stay (LOS) on the ICU. The bar chart depicts all ICU admissions during 2013–2015 (left
vertical axis), black bars indicate the number of admissions with meropenem therapy (MT). The line graph depicts the percentage of admissions
treated with meropenem (right vertical axis) in each LOS group
Fig. 2 Patients disposition
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p = 0.004) and the type of infection (peritonitis vs. pneumo-
nia: OR 16.96, 95% CI 2.95-97.49) were associated with pro-
longed MT (Table 2).
Microbiological data
In the prolonged MT group, 6 patients were colonized
with 3MRGN E. coli and 1 patient with 3MRGN K.
pneumonia. In the control group, 4 patients were colo-
nized with 3MRGN E. coli, 2 patients with 3MRGN K.
pneumoniae and 1 patient with 3MRGN K. oxytoca. One
patient in the prolonged MT group colonized with
3MRGN E. coli and carbapenem-susceptible Enterobac-
ter cloacae developed colonization with carbapenem-
resistant E.coli and E. cloacae during prolonged MT. In
one patient from the prolonged MT group, emergence
of carbapenem-resistant P. aeruginosa was detected dur-
ing MT (anal swab).
Bacterial isolates detected in intraoperative speci-
mens, blood and cerebrospinal fluid (CSF) cultures
of patients with prolonged MT are summarized in
Table 3.
Discussion
In our study, surgical patients with intra-abdominal infec-
tions were at risk for excessively prolonged meropenem
use. The majority of the patients presented with an anas-
tomotic leak requiring repetitive surgical interventions for
source control. Around half of the patients had an initial
surgical procedure for gastrointestinal malignancy.
The duration of antimicrobial therapy in complicated
intra-abdominal infection has been recently studied in a
large randomized controlled trial [9]. In patients with an
adequate source control procedure, the outcomes after
fixed-duration antibiotic therapy of 4 days did not differ
from those after a longer course of antibiotics of 8 days
[9]. In our patients, repetitive surgery reflected
difficulties in source control and the presence of persist-
ent peritonitis. The duration of antibiotic therapy for
persistent peritonitis is not well established [10], the rec-
ommendation in Germany being 7 to 10 days [8]. A lon-
ger duration of antibiotic therapy for intra-abdominal
infections is an independent risk factor for subsequent
intra-abdominal infections and associated with increased
mortality [11].
According to the guidelines of Infectious Diseases So-
ciety of America (IDSA) empiric antibiotic therapy for
health care–associated intra-abdominal infection should
be driven by local microbiology results [12]. In the era of
multidrug-resistance, empirical coverage for MDR bac-
teria may be prudent [10, 13–15]. In our group of surgi-
cal patients, MDR carbapenem-susceptible (so-called
“3MRGN”) isolates were found in 6 patients (23.1%). All
of them were known to be colonized with 3MRGN
Enterobacteriaceae before or at onset of MT. However,
only in 2 of these 6 patients 3MRGN E. coli was also
detected in intraoperative swabs. In consequence, known
colonization - and not necessarily infection - with
3MRGN Enterobacteriaceae was a risk factor for pro-
longed MT in our study. These findings are in accord-
ance with studies that show that intensivists are more
reluctant to de-escalate antimicrobial therapy in patients
with known MDR colonization [16]. Retrospectively, the
number of patients with relevant bacterial isolates at the
site of infection and a clear indication for meropenem
treatment was low (Table 3).
The in-ICU-mortality in patients with excessively
prolonged MT was double as high as in the control
group. It is likely that severe clinical condition prevented
the intensivists from discontinuing meropenem. Of note,
presence of systemic illness in complicated intra-
abdominal infections does not necessitate a longer course
of antimicrobial therapy if source control is obtained [17].
The majority of surgical patients with excessively
prolonged MT had numerous re-operations reflecting dif-
ficulties in source control. In fact, in all patients with peri-
tonitis and excessively prolonged MT the source control
Table 1 Clinical characteristics of patients with prolonged
meropenem therapy (MT) > 4 weeks and controls (ICU-stay >
4 weeks and meropenem therapy ≤ 14 days)
Casesa Controlsb p
Number of patients 36 108
Duration of uninterrupted meropenem
use, days, median (IQR)
34 (31–39) 9 (7–11) <0.001
Age in years, median (IQR) 63 (51–71) 66 (56–73) 0.26
Female sex, n (%) 13 (36.1) 36 (33.3) 0.76
Days on ICU, median (IQR) 66 (51.5–92.5) 35 (31–45) <0.001
Malignancy, n (% of all pts) 17 (47.2) 22 (20.4) 0.002
SAPS score at admission, median (IQR) 42 (35–48) 39 (33–47) 0.36
Medical patients, n (% of all pts) 4 (11.1) 45 (42.7) 0.001
Neurological patients, n (% of all pts) 6 (16.7) 30 (26.9) 0.22
Surgical patients, n (% of all pts) 26 (72.2) 34 (31.5) <0.001
Number of operations, median (IQR)c 14 (5–27) 4 (3–7) <0.001
Colonization/infection with
carbapenem-susceptible, multidrug-
resistant Enterobacteriaceae n (%)
7 (19.4) 7 (6.5) 0.007
Type of infection, n (%)
pneumonia 4 (11.1) 27 (25.0) <0.001
peritonitis 16 (44.4) 5 (4.6)
mediastinitis 6 (16.7) 4 (3.7)
unclear focus 10 (27.8) 72 (66.7)
In-ICU-mortality, n (%) 16 (44.4%) 27 (25.0%) 0.03
apatients with ICU stay > 4 weeks and MT > 28 days
bpatients with ICU stay > 4 weeks and MT ≤ 14 days
cin surgical patients
Abbreviations: IQR: interquartile range SAPS: simplified acute physiology score
MT: meropenem therapy
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was considered as inadequate by the intensivists in charge.
Inability to obtain source control is one of the main
determinants of poor outcome [15]. However, prolonged
broad-spectrum antimicrobial therapy is not likely to
contribute to source control [18, 19]. There is a
growing body of evidence that prolonged antimicro-
bial therapy is not beneficial for critically ill patients
(reviewed in [20]). This might be particularly true for
broad-spectrum antimicrobials where disadvantages of
antibiotic therapy might outweigh unlikely benefits for
the patient [21].
Our study has several limitations. It is a single centre
study in a tertiary care hospital and our experience
might not be representative for all ICU departments.
The retrospective nature of the study does not allow as-
sessment of the contribution of extensively prolonged
MT to clinical outcome. Based on our definition of cases
and controls, the data can be used to identify risk factors
for excessively prolonged use of meropenem (>28 days)
compared to guideline adherent use (≤14 days). How-
ever, we cannot draw conclusions on risk factors for
slightly longer use than recommended by guidelines (i.e.
Table 3 Positive bacterial culture results from sterile sites at onset and during the course of prolonged meropenem therapy
Intraoperative cultures (abdominal, thoracic) blood cultures CSF, brain tissue
Enterococcus faecium, n = 7
Enterococcus faecalis, n = 6
Stenotrophomonas maltophilia, n = 6
multidrug-resistant, carbapenem-susceptible Escherichia coli, n = 2a
Enterobacter cloacae complex, n = 2
Coagulase-negative staphylococci, n = 2
Pseudomonas aeruginosa, n = 1
Proteus mirabilis, n = 1
Proteus vulgaris, n = 1
Klebsiella pneumoniae, n = 1
Escherichia coli (non MRGN), n = 1
Staphylococcus aureus, n = 1
Enterococcus gallinarum, n = 1
E. faecalis, n = 1




E. aerogenes, n = 1
E. cloacae, n = 1
S. maltophilia, n = 1
multidrug-resistant,
carbapenem-resistant
P.aeruginosa, n = 1
Staphylococcus aureus, n = 1
Staphylococcus epidermidis,
n = 1
Proteus mirabilis, n = 1
Bacteroides fragilis, n = 1
aisolates that require unequivocally carbapenem therapy
Abbreviations: n number of patients; CSF cerebrospinal fluid
Table 2 Analysis of potential risk factors for excessively prolonged meropenem therapy
Univariate logistic regression Multivariate logistic regression
OR 95% CI P-value OR 95% CI P-value
age <50 1 0.44 - - -
50-70 0.72 0.25–2.04
≥70 0.49 0.16–1.53
sex male 1 0.76 - - -
female 1.13 0.51–2.49
malignancy No 1 0.002 1 0.84
Yes 3.5 1.57–7.82 1.14 0.32–4.06
SAPS at admission <40 1 0.33 - - -
≥40 1.45 0.68–3.11
patient group medical 1 <0.001 1 0.31
neurological 2.41 0.63–9.30 2.79 0.65 – 11.92
surgical 8.36 2.67–26.17 2.46 0.50 – 11.98
colonization with carbapenem-susceptible, MDR bacteria no 1 0.01 1 0.004
yes 4.12 1.38–12.35 7.52 1.88–30.14
type of infection pneumonia 1 <0.001 1 <0.001
peritonitis 21.60 5.05–92.35 16.96 2.95 – 97.49
mediastinitis 10.12 1.96–52.41 6.27 0.81 – 48.76
unclear focus 0.94 0.27–3.24 0.77 0.21 – 2.84
Full model containing all variables with at least some evidence of association (p < 0.1) with the outcome in univariate regression analysis
Abbreviations: MDR multidrug-resistant; OR: odds ratio; 95% CI: 95% confidence Interval
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14–28 days). This group of patients is surely more het-
erogeneous than the cases in this study and should be
included in the focus of future, larger studies.
Due to the small number of patients the power of the
study was low, as reflected by wide 95% confidence in-
tervals and several potential risk factors may not have
been identified. Due to the low number of patients it
was not possible to study the emergence of carbapenem-
resistant (so-called 4MRGN) microorganisms under
prolonged MT. However, detection of carbapenem-
resistant E. coli and E. cloacae isolates after prolonged
MT in one patient with known colonization with
multidrug-resistant carbapenem-susceptible isolates and
the emergence of carbapenem-resistant P. aeruginosa in
another patient are worrying signs [22, 23].
Conclusion
Surgical patients with persistent peritonitis are at risk for
excessively prolonged carbapenem therapy. Antimicrobial
stewardship programmes should target this patient group
to prevent overuse of last resort antimicrobials.
Abbreviations
CSF: Cerebrospinal fluid; ICU: Intensive care unit; IDSA: Infectious Diseases
Society of America; LOS: Length of stay; MDR: Multidrug-resistant;
MRGN: Multidrug-resistant Gram-negative bacteria; MRSA: Methicillin-resistant
S. aureus; MT: Meropenem therapy; OR: Odds ratio; SAPS: Simplified Acute
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